SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1159Acquisitions During the call yesterday Lynch touched upon their current thinkinIcebrg-7/25/2003
1158Looks like that they are moving few months into '04. Adding more pts in ongoMiljenko Zuanic-7/24/2003
1157still listed........ syrrx.com <i>Wendell Wierenga, Ph.D. Chief Executivscaram(o)uche-7/24/2003
1156September? Wonder what is happening with Syrrx? Bravo!! Great catch, and it fscaram(o)uche-7/24/2003
1155<pre> Quarterly figures Q2_03 Q1_03 Q4_02 Q3_02 Q2_02 Q1_02Icebrg-7/24/2003
1154Date for Indiplon IND filing. I wonder if they just slipped a couple of months.Icebrg-7/24/2003
1153Neurocrine, Sepracor Race To Unseat Ambien For Insomnia By Randall Osborne EditoIcebrg-7/19/2003
1152Body weight regulation by selective MC4 receptor agonists and antagonists. FostIcebrg-7/13/2003
1151Neurocrine Biosciences initiated with "outperform" Message 19068042Icebrg-6/27/2003
1150Just to remind us, the company is pushing the gnrh b/u compounds to seek longer keokalani'nui-6/24/2003
1149Neurocrine Biosciences Announces Positive Phase I Results With Its Proprietary, Icebrg-6/24/2003
1148Indiplon (Insomnia) [S G Cowen comments following Pfizer's analysts' prIcebrg-6/18/2003
1147great tidbit, thanks! (eom)scaram(o)uche-6/18/2003
1146Wilder, Here is the portion of GS's comment relating to PFE that addresses quidditch-6/18/2003
1145After pfe's analyst meeting, gs's pharma analyst apparently brought indikeokalani'nui-6/18/2003
1144Financial development - 12m figures. <pre> 2000 2001 2002 Icebrg-6/15/2003
1143Neurocrine Biosciences "buy," target price raised -update [Not that iIcebrg-6/9/2003
1142Erik, Yes Provigil and Estorra fit well together, but Estorra will not be cheapMiljenko Zuanic-6/8/2003
1141Miljenko. >>I see very, very slim chance that FDA will reject Indiplon>Icebrg-6/8/2003
1140I see very, very slim chance that FDA will reject Indiplon. The question is labeMiljenko Zuanic-6/8/2003
1139Miljenko >> I do not understand why you are talking about Indiplon *disasIcebrg-6/7/2003
1138I do not understand why you are talking about Indiplon *disaster*, and what you Miljenko Zuanic-6/7/2003
1137>> so strike while the iron is hot, since it may dry up again just as quicIcebrg-6/7/2003
1136<i> This is a little bit of a mystery here </i> Not really. one comopgcw-6/7/2003
1135Maybe a munch NIBX was considering just got $200 m more expensive amid the recenquidditch-6/6/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News